Loading...
Loading...
CLNN| Name | Value |
|---|---|
| Revenues | 269.0K |
| Cost of Revenue | 66.0K |
| Gross Profit | 203.0K |
| Operating Expense | 9,739.0K |
| Operating I/L | -10,336.0K |
| Other Income/Expense | -14,807.0K |
| Interest Income | 213.0K |
| Pretax | -25,143.0K |
| Income Tax Expense | -13,752.0K |
| Net Income/Loss | -25,143.0K |
Clene Inc. is a clinical-stage pharmaceutical company specializing in the development and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug, CNM-Au8, is undergoing clinical trials for various conditions including ALS, Parkinson's Disease, and Multiple Sclerosis. The company also offers CNM-AgZn17 for infectious diseases and wound healing, CNM-ZnAg for antiviral and antibacterial applications, and CNM-PtAu7 for oncology. Additionally, Clene Inc. markets dietary supplements such as rMetx and KHC46. The company generates revenue through the development, clinical trials, and commercialization of its pharmaceutical and therapeutic products, as well as the sale of dietary supplements.
